These findings were validated using the MEK inhibitor selumetinib and the BCL-XL inhibitor ABT-263 in a genetically engineered KRAS-driven mouse model of lung cancer; highlighting the potential clinical relevance of this interaction. Here, KRAS is linked to lung carcinoma.